Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-08-30
DOI
10.1111/1759-7714.12815
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
- (2018) Y. Fujisawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
- (2018) Wungki Park et al. Clinical Lung Cancer
- Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
- (2018) Alessandro Russo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
- (2018) Samuel Rosner et al. Cancer Medicine
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
- (2017) Roger Sun et al. EUROPEAN JOURNAL OF CANCER
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma
- (2017) Jun Yin et al. MEDICINE
- Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients
- (2017) Xu Liu et al. MEDICINE
- Review of cancer treatment with immune checkpoint inhibitors
- (2017) Christiane Thallinger et al. WIENER KLINISCHE WOCHENSCHRIFT
- Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
- (2017) Minkyu Jung et al. Cancer Research and Treatment
- Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer
- (2017) Takayuki Shiroyama et al. Cancer Medicine
- Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- (2017) Ghayathri Jeyakumar et al. Journal for ImmunoTherapy of Cancer
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
- (2016) Tomohiro F. Nishijima et al. CANCER TREATMENT REVIEWS
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
- (2016) Katrin Moses et al. SEMINARS IN IMMUNOLOGY
- Adapting Cancer Immunotherapy Models for the Real World
- (2016) Lauryn E. Klevorn et al. TRENDS IN IMMUNOLOGY
- The Role of Prostaglandin E 2 in Tumor-Associated Immunosuppression
- (2016) Dingzhi Wang et al. TRENDS IN MOLECULAR MEDICINE
- The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
- (2016) Leila Khoja et al. Cancer Medicine
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
- (2015) J. Zaragoza et al. BRITISH JOURNAL OF DERMATOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
- (2014) A. M. Di Giacomo et al. ANNALS OF ONCOLOGY
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based study
- (2012) Freddie Bray et al. LANCET ONCOLOGY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now